Toponome Mapping in Prostate Cancer: Detection of 2000 Cell Surface Protein Clusters in a Single Tissue Section and Cell Type Specific Annotation by Using a Three Symbol Code

2009 ◽  
Vol 8 (6) ◽  
pp. 2696-2707 ◽  
Author(s):  
Walter Schubert ◽  
Anne Gieseler ◽  
Andreas Krusche ◽  
Reyk Hillert
Keyword(s):  
Prostate Cancer ◽  
Cell Surface ◽  
Cancer Detection ◽  
Surface Protein ◽  
Cell Surface Protein ◽  
Cell Type ◽  
Prostate Cancer Detection ◽  
Protein Clusters ◽  
Symbol Code ◽  
Cell Type Specific

DPP4 inhibitors as novel agents in improving survival in patients with prostate cancer: A SEER-Medicare study.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e16532-e16532
Author(s):  
Chintan Shah ◽  
Young-Rock Hong ◽  
Rohit Bishnoi ◽  
azka ali ◽  
William Paul Skelton ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cell Surface ◽  
Tumor Biology ◽  
Prospective Trial ◽  
Surface Protein ◽  
Cell Surface Protein ◽  
Cellular Mechanisms ◽  
Dpp4 Inhibitors ◽  
The Impact

e16532 Background: Dipeptidyl peptidase-4 (DPP4) is a cell surface protein expressed in variable amounts on different tissues and plays a vital role in tumor biology as well as regulation of the immune system. In-vitro studies have shown that the DPP4 biochemical activity is twice as high in prostate cancer cells compared to benign prostate tissues. Furthermore, blocking of DPP4 activity in-vitro was demonstrated to inhibit tumor angiogenesis and tumor invasiveness through a number of cellular mechanisms. Meanwhile, DPP4 expression is modest in normal as well as cancerous pancreatic cells. Methods: Using linked SEER and MEDICARE database, we identified patients with prostate cancer (PRC) or pancreatic cancer (PC) with coexisting type II diabetes mellitus. Furthermore, we analyzed the impact of DPP4 inhibition in the overall survival (OS) in these patients between 2001 and 2013. Analyses were performed using SAS, version 9.4. We excluded patients taking metformin. Results: We identified 7229 patients with PRC and 2401 patients with PC. OS was significantly better in PRC patients taking DPP4 inhibitors (262 patients) with HR 0.75 (95% CI: 0.59-0.97; P = 0.02) compared to those not on DPP4 inhibitors. Meanwhile, for patients with PC, OS was not significantly different between patients taking DPP4 inhibitors (177 patients) compared to those who were not (HR 1.03; 95% CI: 0.88-1.21; P = 0.7). Subgroup analyses of PRC patients demonstrated a trend toward a beneficial effect of DPP4 inhibitors, irrespective of stage (stage I, NR; stage II, HR 0.81; stage III, NR; stage IV, 0.76),use of chemotherapy (HR 0.83 with chemotherapy and HR 0.70 without chemotherapy) or hormonal use (ADT) (HR 0.87 with ADT and HR 0.71 without ADT), prostatectomy (HR 0.50 with prostatectomy and HR 0.77 with no prostatectomy) or radiation (HR 0.89 with radiation and HR 0.64 without radiation). Conclusions: This is the first population-based analysis showing the OS benefit of DPP4 inhibitors in PRC patients. On the other hand, OS was not improved in PC patients taking DPP4 inhibitors likely due to low levels of expression of DPP4 cell surface protein on pancreatic tissues. A prospective trial would help confirm our findings.

Ability of a cell-surface protein produced by fibroblasts to modify tissue affinity behaviour of cardiac myocytes

1980 ◽  
Vol 44 (1) ◽  
pp. 263-271
Author(s):  
P.B. Armstrong
Keyword(s):  
Cell Surface ◽  
Cell Movement ◽  
Surface Protein ◽  
Heart Tissue ◽  
Cell Surface Protein ◽  
Cell Type ◽  
Heart Ventricle ◽  
Embryonic Tissues ◽  
Culture Cells ◽  
A Cell

When fragments of 2 dissimilar embryonic tissues are placed in contact in organ culture, cells of one fragment migrate over the surface of the second to envelop it. Holtfreter proposed that this behaviour was in response to ‘tissue affinities’. He proposed that these also play important roles in the control of morphogenetic cell movement during development. The present study demonstrates that the heart fibroblast, present as a minority cell type in heart ventricle, can modify the affinity behaviour of heart tissue. The fibroblast effect appears to be mediated by a factor that can be extracted from living fibroblast monolayers by 1 M urea. The factor is a cell-surface protein since it is absent in monolayers which had been treated with trypsin prior to extraction.

Immunogold and immunoblot studies on a cell surface protein found in primary mesenchyme cells and in the cortical secretory vesicles of the sea urchin egg

1987 ◽  
Vol 45 ◽  
pp. 832-833
Author(s):  
G.L. Decker ◽  
M.C. Valdizan
Keyword(s):  
Cell Surface ◽  
Sea Urchin ◽  
Surface Protein ◽  
Egg Cell ◽  
Secretory Vesicles ◽  
Cell Surface Protein ◽  
Surface Complexes ◽  
Mesenchyme Cells ◽  
Lowicryl K4m ◽  
Primary Mesenchyme Cells

A monoclonal antibody designated MAb 1223 has been used to show that primary mesenchyme cells of the sea urchin embryo express a 130-kDa cell surface protein that may be directly involved in Ca2+ uptake required for growth of skeletal spicules. Other studies from this laboratory have shown that the 1223 antigen, although in relatively low abundance, is also expressed on the cell surfaces of unfertilized eggs and on the majority of blastomeres formed prior to differentiation of the primary mesenchyme cells.We have studied the distribution of 1223 antigen in S. purpuratus eggs and embryos and in isolated egg cell surface complexes that contain the cortical secretory vesicles. Specimens were fixed in 1.0% paraformaldehyde and 1.0% glutaraldehyde and embedded in Lowicryl K4M as previously reported. Colloidal gold (8nm diameter) was prepared by the method of Mulpfordt.

1508: Obesity, Serum PSA, and Prostate Size: Implications for Prostate Cancer Detection

2006 ◽  
Vol 175 (4S) ◽  
pp. 487-487
Author(s):  
Stephen J. Freedland ◽  
Elizabeth A. Platz ◽  
Joseph C. Presti ◽  
William J. Aronson ◽  
Christopher L. Amling ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Prostate Cancer Detection ◽  
Prostate Size

1476: Prostate Cancer Detection in Men Aged 45-49 Years in the UK Protect (Prostate Testing for Cancer and Treatment) Trial

2006 ◽  
Vol 175 (4S) ◽  
pp. 476-477
Author(s):  
Freddie C. Hamdy ◽  
Joanne Howson ◽  
Athene Lane ◽  
Jenny L. Donovan ◽  
David E. Neal
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Treatment Trial ◽  
Prostate Cancer Detection ◽  
The Uk

1962: Correlation between Prostate Cancer Detection Rate and Gland Volume: Is Increased Biopsy Sampling Needed for Patients with a Large Prostate?

2007 ◽  
Vol 177 (4S) ◽  
pp. 651-651
Author(s):  
Nicolas B. Delongchamps ◽  
Vishal Chandan ◽  
Richard Jones ◽  
Gregory Threatte ◽  
Mary Jumbelic ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Detection Rate ◽  
Cancer Detection Rate ◽  
Prostate Cancer Detection ◽  
Gland Volume ◽  
Large Prostate

477: Body Mass Index and Impact on PSA Screening and Prostate Cancer Detection in the Plco Trial

2006 ◽  
Vol 175 (4S) ◽  
pp. 155-155
Author(s):  
Robert L. Grubb ◽  
David L. Levin ◽  
Paul F. Pinsky ◽  
Jerome Mabie ◽  
Thomas L. Riley ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Cancer Detection ◽  
Prostate Cancer Detection ◽  
Psa Screening

448: Prostate Cancer Detection and PSA Increaseafter 4 Years in Dutch and Japanese Males Without Evidence of Disease at Initial Screening

2004 ◽  
Vol 171 (4S) ◽  
pp. 118-119
Author(s):  
Kazuto Ito ◽  
René Raaijmakers ◽  
Monique J. Roobol ◽  
Mark F. Wildhagen ◽  
Hidetoshi Yamanaka ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Detection ◽  
Initial Screening ◽  
Prostate Cancer Detection
Sign in / Sign up

Export Citation Format

Share Document